Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant Aβ in plasma

Neurobiology of Disease

Volumn 24, Issue 1, 2006, Pages 114-127

  Burgess, Braydon L ^a   McIsaac, Sean A ^a   Naus, Kathryn E ^a   Chan, Jeniffer Y ^a   Tansley, Gavin H K ^a   Yang, Jing ^b   Miao, Fudan ^a   Ross, Colin J D ^a   van Eck, Miranda ^c   Hayden, Michael R ^a   van Nostrand, William ^d   St George Hyslop, Peter ^b   Westaway, David ^b   Wellington, Cheryl L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c LEIDEN UNIVERSITY   (Netherlands)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

A ; Alzheimer's Disease; Amyloid; Cholesterol; Triglyceride; Very low density lipoprotein

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; INFLAMMATION; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; DNA, COMPLEMENTARY; FATTY ACIDS, NONESTERIFIED; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; KETONES; LIPASE; LIPOPROTEIN LIPASE; LIVER; MICE; MICE, TRANSGENIC; TRIGLYCERIDES;

EID: 33748781703     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.06.007     Document Type: Article

References (94)

1. Adunsky A., Chesnin V., Davidson M., Gerber Y., Alexander K., and Haratz D. A cross-sectional study of lipids and apoC levels in Alzheimer's patients with and without cardiovascular disease. J. Gerontol., A Biol. Sci. Med. Sci. 57 (2002) M757-M761
2. Allayee H., Ghazalpour A., and Lusis A.J. Using mice to dissect genetic factors in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1501-1509
3. Bales K.R., Du Y., Holtzman D., Cordell B., and Paul S.M. Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Ab-induced glial activation, NF-kB, and apolipoprotein E. Neurobiol. Aging 21 (2000) 427-432
4. Blasko I., Stampfer-Kountchev M., Robatscher P., Veerhuis R., Eikelenboom P., and Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 3 (2004) 169-176
5. Bodovitz S., and Klein W.L. Cholesterol modulates a-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271 (1996) 4440
6. Borggreve S.E., De Vries R., and Dullaart R.P.F. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur. J. Clin. Invest. 33 (2003) 1051-1069
7. Burns M., Gaynor K., Olm V., Mercken M., LaFrancois J., Wang L., Matthews P.M., Noble W., Matsuoka Y., and Duff K. Presenilin redistribution associated with aberrant cholesterol transport enhances β-amyloid production in vivo. J. Neurosci. 23 (2003) 5645-5649
8. Buxbaum J.D., Geoghagan N.S., and Friedhoff L.T. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J. Alzheimer's Dis. 3 (2001) 221-229
9. Buxbaum J.D., Cullen E.I., and Friedhoff L.T. Pharmacological concentrations of the HMG-CoA reducatase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid in vitro and in patients. Front. Biosci. 7 (2002) 50-59
10. Cankurtaran M., Yavuz B.B., Halil M., Dagli N., Cankurturan E.S., and Ariogyl S. Are serum lipid and lipoprotein levels related to dementia?. Arch. Gerontol. Geriatr. 41 (2005) 31-39
11. Casserly I., and Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363 (2004) 1139-1146
12. Chishti M.A., Yang D.-S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., St.George-Hyslop P., and Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276 (2001) 21562-21570
13. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
14. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Protective effect of apolipoprotein E type 2 for late onset Alzheimer disease. Nat. Genet. 7 (1994) 180-184
15. Davis J., Xu F., Deane R., Romanov G., Previti M.L., Zeigler K., Zlokovic B.V., and Van Nostrand W.E. Early-onset and robust cerebral microvascular accumulation of amyloid {beta}-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid {beta}-protein precursor. J. Biol. Chem. 279 (2004) 20296-20306
16. Ehehalt R., Keller P., Haass C., Thiele C., and Simons K. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 (2003) 113-123
17. Fassbender K., Simons M., Bergmann C., Stroick M., Lütjohann D., Keller P., Runz H., Kühl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., and Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Ab42 and Ab40 in vitro and in vivo. Proc. Natl. Acad. Sci. 98 (2001) 5856-5861
18. Ghiso J., Shayo M., Calero M., Ng D., Tomidokoro Y., Gandy S., Rostagno A., and Frangione B. Systemic catabolism of Alzheimer's Abeta 40 and Abeta 42. J. Biol. Chem. 279 (2004) 45897-45908
19. Goldberg I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. JLR 37 (1996) 693-707
20. Hajjar I., Schumpert J., Hirth V., Wieland D., and Eleazer G.P. The impact of the use of statins on the prevalance of dementia and the progression of cognitive impairment. J. Gerontol., A, Biol. Sci. Med. Sci. 57 (2002) M414-M418
21. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
22. Hoglund K., Thelen K.M., Syversen S., Sjogren M., von Bergmann K., Wallin A., Vanmechelen E., Vanderstichele H., Lutjohann D., and Blennow K. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 19 (2005) 256-265
23. Hone E., Martins I.J., Fonte J., and Martins R.N. Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J. Alzheimer's Dis. 5 (2003) 1-8
24. Honig L.S., Kukull W., and Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's coordinating center. Neurology 64 (2005) 494-500
25. James A.P., Pal S., Gennat H.C., Vine D.F., and Mamo J.C.L. The incorporation and metabolism of amyloid-β into chylomicron-like lipid emulsions. J. Alzheimer's Dis. 5 (2003) 179-188
26. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., and Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ-secretase. Hum. Mol. Genet. 13 (2003) 159-170
27. Jick H., Zornberg G.L., Jick S.S., Sashadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
28. Julius U. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp. Clin. Endocrinol. Diabetes 111 (2003) 246-250
29. Khovidhunkit W., Kim M.S., Memon R.A., Shigenaga J.K., Moser A.H., Feingold K.R., and Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolsim: mechanisms and consequences to the host. J. Lipid Res. 45 (2004) 1169-1196
30. Kivipelto M., Helkalal E.-L., Laakso M.P., Hänninen T., Hallikainen M., Alheinen K., Soininen H., Tuomilehto J., and Nissien A. Midlife vascular risk factors and Alzhiemer's disease in later life: longitudinal, population based study. BMJ 322 (2001) 1447-1451
31. Kivipelto M., Helkalal E.-L., Laakso M., Hänninen T., Hallikainen M., Alhainen K., Ilvonen S., Mannermaa A., Tuomilehto J., Nissinen A., and Solninen H. Apolipoprotein E e4 allele, elevated midlife total cholesterol leve, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137 (2002) 149-155
32. Kojro E., Gimple G., Lammich S., März W., and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. 98 (2001) 5815-5820
33. Kolovou G.D., Anagnostopoulou K.K., and Cokkinos D.V. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad. Med. J. 81 (2005) 358-366
34. Koudinov A.R., Matsubara E., Frangione B., and Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem. Biophys. Res. Commun. 205 (1994) 1164-1171
35. Koudinov A.R., Koudinova N.V., Kumar A., Beavis R.C., and Ghiso J. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem. Biophys. Res. Commun. 223 (1996) 592-597
36. Koudinov A.R., Berezov T.T., Kumar A., and Koudinova N.V. Alzheimer's amyloid b interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin. Chim. Acta 270 (1998) 75-84
37. Koudinov A.R., Berezov T.T., and Koudinov N.V. The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implication for brain cholesterol pathology?. Neurosci. Lett. 314 (2001) 115-118
38. Kuipers F., Jong M.C., Lin Y., van Eck M., Havinga R., Bloks V., Verkade H.J., Hofker M.H., Moshage H., van Berkel T.J.C., Vonk R.J., and Havekes L.M. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. JCI 100 (1997) 2915-2922
39. Li L., Cao D., Garber D.W., Kim H., and Fukuchi K. Association of aortic atherosclerosis with cerebral β-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am. J. Pathol. 163 (2003) 2155-2164
40. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen Moore K., Tsuang D., van Belle G., McCormick W., Bowen J.D., Teri L., Schellenberg G.D., and Larson E.B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 (2004) 1624-1628
41. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., Casadei V., and Grimaldi L.M.E. Increased plasma levels of interleukin-1, interleukin-6 and a-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J. Neuroimmunol. 103 (2000) 97-102
42. Locatelli S., Lütjohann D., Schmidt H.H.J., Carsten O., Beiseiegel U., and von Bergmann K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia. Arch. Neurol. 59 (2002) 213-216
43. Mahley R.W., and Rall S.C.Jr. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1 (2000) 507-537
44. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., and Mehta P.D. Plasma A{beta}40 and A{beta}42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61 (2003) 1185-1190
45. Mehta P.D., Pirttilä T., Mehta S.P., Sersen E.A., Aisen P.S., and Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57 (2000) 100-105
46. Merched A., Xia Y., Visvikis S., Serot J.M., and Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 21 (2000) 27-30
47. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?. J. Neurosci. Res. 72 (2003) 141-146
48. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383-421
49. Nilsson-Ehle P., and Schotz M.C. A stable, radioactive substrate emulsion for assay of lipoprotein lipase. JLR 17 (1976) 536-541
50. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., and Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17 (1998) 14-20
51. Oesch B., Westaway D., Wälchli M., McKinley M.P., Kent S.B.H., Aebersold R., Barry R.A., Tempst P., Teplow D.B., Hood L.E., Pruisiner S.B., and Weissmann C. A cellular gene encodes scrapie PrP27-30 protein. Cell 40 (1985) 735-746
52. Paigen B., Morrow A., Brandon C., Mitchell D., and Holmes P.A. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57 (1985) 65-73
53. Paigen B., Holmes P.A., Mitchell D., and Albee D. Comparison of atherosclerotic lesions and HDL lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H. Atherosclerosis 64 (1987) 215-221
54. Pappolla M.A., Bryant-Thomas T.K., Herbert D., Pacheco J., Fabra Garcia M., Manjon M., Girones X., Henry T.L., Matsubara E., Zambon D., Wolozin B., Sano M., Cruz-Sanchez F.F., Thal L.J., Petanceska S.S., and Refolo L.M. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61 (2003) 199-205
55. Perry V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav. Immun. 18 (2004) 407-413
56. Puglielli L., Konopka G., Pack-Chung E., Mac Kenzie Ingano L.A., Berezovska O., Hyman B.T., Chang T.Y., Tanzi R.E., and Kovacs D.M. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nat. Cell Biol. 3 (2001) 905-912
57. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6 (2003) 345-351
58. Raffaï R.L., and Weisgraber K.H. Cholesterol: from heart attacks to Alzheimer's diseases. J. Lipid Res. 44 (2003) 1423-1430
59. Raz I., Eldor R., Cernea S., and Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes/Metab. Res. Rev. 31 (2005) 3-14
60. Refolo L.M., Pappolla M.A., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., and Duff K. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7 (2000) 321-331
61. Refolo L.M., Pappolla M.A., LaFrancois J., Malester B., Schmidt S.D., Thomas-Bryant T., Tint G.S., Wang R., Mercken M., Petanceska S.S., and Duff K.E. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8 (2001) 890-899
62. Reitz C., Tang M.X., Luchsinger J., and Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 61 (2004) 705-714
63. Rockwood K. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59 (2002) 223-227
64. Rodriguez E.G., Dodge H.H., Birzescu M.A., Stoehr G.P., and Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J. Am. Geriatr. Soc. 50 (2002) 1852-1856
65. Romas S.N., Tang M.X., Berglund L., and Mayeux R. ApoE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53 (1999) 517-521
66. Sabbagh M., Sahiri H.R., Ceimo J., Cooper K., Gaul W., Connor D., and Sparks D.L. Is there a characteristic lipid profile in Alzheimer's disease. J. Alzheimer's Dis. 6 (2004) 585-589
67. Santamarina-Fojo S., González-Navarro H., Freeman L., Wagner E., and Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1750-1754
68. Santanello N.C., Barber B.L., Applegate W.B., Elam J., Curtis C., Hunninghake D.B., and Gordon D.J. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the cholesterol reduction in seniors program (CRISP) pilot study. J. Am. Geriatr. Soc. 45 (1997) 8-14
69. Scharnagl H., Tisljar U., Winkler K., Huttinger M., Nauck M.A., Gross W., Wieland H., Ohm T.G., and Marz W. The betaA4 amyloid peptide complexes to and enhances the uptake of beta-very low density lipoproteins by the low density lipoprotein receptor-related protein and heparan sulfate proteoglycans pathway. Lab. Invest. 79 (1999) 1271-1286
70. Schmechel D., and Sullivan P. High saturated fat diets are associated with Ab deposition in primates. Neurobiol. Aging 23 (2002) 323-329
71. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L.E.M., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C., and Westendorp R.G.J. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
72. Shie F.S., Jin L.W., Cook D.G., Leverenz J.B., and LeBoeuf R.C. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. NeuroReport 213 (2002) 455-459
73. Simons M., Keller P., De Strooper B., Beyreuther K., Dottie C.G., and Simons K. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. 95 (1998) 6460-6464
74. Simons M., Schwärzler F., Lutjohann D., von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T., and Schulz J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled double blind trial. Ann. Neurol. 52 (2002) 346-350
75. Sjogren M., Gustafsson K., Syversen S., Olsson A., Edmann A., Davidsson P., Wallin A., and Blennow K. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement. Geriatr. Cogn. Disord. 16 (2003) 25-30
76. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., Wasser D., Johnson-Traver S., Lochhead J., and Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease. Arch. Neurol. 62 (2005) 753-757
77. Strittmatter W.J., and Roses A.D. Apolipoprotein E and Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 4725-4727
78. Stuchbury G., and Münch G. Alzheimer's associated inflammation, potential drug targets and future therapies. J. Neural Transm. 112 (2005) 429-453
79. Sun Y.X., Minthon L., Wallmark A., Warkentin S., Blennow K., and Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 16 (2003) 136-144
80. Suryadevara V., Storey S.G., Aronow W.S., and Ahn C. Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J. Gerontol., A, Biol. Sci. Med. Sci. 58 (2003) M859-M861
81. Szapary P.O., and Rader D.J. The triglyceride-high-density lipoprotein axis: an important target of therapy?. Am. Heart J. 148 (2004) 211-221
82. Tsukamoto K., Maugeais C., Glick J.M., and Rader D.J. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice. J. Lipid Res. 41 (2000) 253-259
83. Vega G.L., Weiner M.F., Lipton A.M., von Bergmann K., Lutjohann D., Moore C., and Svetlik D. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol. 60 (2003) 510-515
84. Wahrle S., Das P., Nyborg A.C., McLendon C., Shoji M., Kawarabayashi T., Younkin L.H., Younkin S.G., and Golde T.E. Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9 (2002) 11-23
85. Wellington C.L., Walker E.K., Suarez A., Kwok A., Bissada N., Singaraja R., Yang Y.-Z., Zhang L.H., James E., Wilson J.E., Francone O., McManus B.M., and Hayden M.R. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab. Invest. 82 (2002) 273-283
86. Whitmer R.A., Sidney S., Selby J., Claibourne Johnston S., and Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64 (2005) 277-281
87. Wilson L.M., Pham C.L., Jenkins A.J., Wade J.D., Hill A.F., Perugini M.A., and Howlett G.J. High density lipoproteins bind Ab and apolipoprotein C-II amyloid fibrils. J. Lipid Res. 47 4 (2006) 755-760
88. Wirths O., Thelen K., Breyhan H., Luzón-Toro B., Hoffmann K.-H., Falkai P., Lütjohann D., and Bayer T.A. Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Exp. Gerontol. 41 2 (2005) 220-224
89. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 41 (2004) 7-10
90. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
91. Yaffe K., Barret-Connor E., Lin F., and Grady D. Serum lipoprotein levels, stain use, and cognitive function in older women. Arch. Neurol. 59 (2002) 378-384
92. Yoshitake T., Kiyohara Y., Kato I., Ohmura T., Iwamoto H., Nakayama K., Ohmori S., Nomiyama K., Kawano H., Ueda K., Sueishi K., Tsuneyoshi M., and Fijishima M. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology (1995) 1161-1168
93. Zaldy S.T., Seshardri S., Beiser A., Wilson P.W.F., Kiel D.P., Tocco M., D'Agostino R.B., and Wolf P.A. Plasma total cholesterol level as a risk factor for Alzheimer disease. Arch. Intern. Med. 163 (2003) 1053-1057
94. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., and Breitner J.C.S. Do statins reduce risk of incident dementia and Alzheimer's disease?: The Cache County Study. Arch. Gen. Psychiatry 62 (2005) 217-224